Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

Ads

You May Also Like

Curetis Publishes Interim Report for the First Half-Year 2018

Curetis Publishes Interim Report for the First Half-Year 2018 Amsterdam, the Netherlands, San Diego, ...

Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference

BOSTON, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated ...